People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Health Care, Other, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2013 |
| Daktari Diagnostics, Inc. | — | Biotechnology | Series B | $76.3M | $893.0M | 2009 |
| CranioVation, Inc. | — | Other Health Care | Series B | $56.7M | $174.9M | 2020 |
| Podimetrics, Inc. | — | Other | Series C | $55.3M | $578.9M | 2012 |
| Lexington Medical, Inc. | — | Manufacturing | Series B | $37.8M | $180.2M | 2025 |
| Nanopath Inc | — | Biotechnology | Series A | $15.3M | $21.3M | 2025 |
| Syncro Medical Innovations Inc | — | Biotechnology | Pre-Seed | $3.0M | $13.8M | 2009 |
Aaron Sandoski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aaron Sandoski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| Carter Meyer | 1 | 14 |
| David Roberts | 1 | 13 |
| Jeffrey Crowe | 1 | 12 |
| David Rubin | 1 | 11 |
| Ann DeWitt | 1 | 10 |
| Jeff Crowe | 1 | 9 |
| Peter Kolchinsky | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| Stanley Lapidus | 1 | 7 |
| Robert Stein | 1 | 6 |
| Klaus Veitinger | 1 | 6 |
| Roger Kitterman | 1 | 5 |
| Andrew ` Offer | 1 | 5 |
| Juan-Pablo Mas | 1 | 5 |
| Rachel Sha | 1 | 4 |
| Edward Roberts | 1 | 3 |
| Michael Schrader | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.